Mean Percentage Improvement in Psoriasis Area and Severity Index (PASI) Response and Absolute PASI Through 5 Years of Continuous  Treatment With Guselkumab (GUS) in VOYAGE 1

Joe Merola; Luis Puig; Megan  Miller; Yin You; Yaung-Kaung  Shen; Ya-Wen Yang; Andrew  Blauvelt

doi:10.25251/skin.6.supp.3

Joe Merola

Brigham and Women’s Hospital

Luis Puig

Autonomous University of Barcelona

Megan Miller

Janssen Research and Development

Yin You

Janssen Research and Development

Yaung-Kaung Shen

Janssen Research and Development

Ya-Wen Yang

Janssen Research and Development

Andrew Blauvelt

Oregon Medical Research Center, Portland, OR, USA

Keywords

psoriasis

Abstract

N/A

References

1. Blauvelt A, et al. J Am Acad Dermatol. 2017;76(3):405-417

Poster PDF

Published

Mar 4, 2022

DOI https://doi.org/10.25251/skin.6.supp.3

How to Cite

Merola, J., Puig, L., Miller, M. ., You, Y., Shen, Y.-K. ., Yang, Y.-W., & Blauvelt, A. . (2022). Mean Percentage Improvement in Psoriasis Area and Severity Index (PASI) Response and Absolute PASI Through 5 Years of Continuous Treatment With Guselkumab (GUS) in VOYAGE 1 . SKIN The Journal of Cutaneous Medicine, 6(2), s3. https://doi.org/10.25251/skin.6.supp.3

Issue

Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)

Section

Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Kim Papp, Kristian Reich, Andrew Blauvelt, Diamant Thaci, Rodney Sinclair, Stephen K Tyring, Nicole Cichanowitz, Stuart Green, Qing Li, Carmen La Rosa, Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Kim A Papp, Joseph F Merola, Alice B Gottlieb, Christopher EM Griffiths, Kristina K Harris, Nancy Cross, Luke Peterson, Christopher Cioffi, Andrew Blauvelt, Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Andrew Blauvelt, Andrew Pink, Margitta Worm, Richard Langley, Antonio Costanzo, Le Gjerum, Emilie Jorgensen, Joshua Corriveau, Emma Guttman-Yassky, COVID-19 in tralokinumab-treated patients with moderate-to- severe atopic dermatitis: case series from the ECZTEND long- term extension trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Kristian Reich, Andrew Blauvelt, Diamant Thaci, Craig Leonardi, Yves Poulin, Daniel Burge, Luke Peterson, Catherine Arendt, Alice B Gottlieb, Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Matthias Augustin, Jolanta Weglowska, Mark Lebwohl, Carle Paul, Vincent Piquet, Howard Sofen, Andrew Blauvelt, Daniel Burge, Luke Peterson, Janice Drew, Robert Rollen, Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT) , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Andrew Blauvelt, Kristian Reich, Mark Lebwohl, Daniel Burge, Catherine Arendt, Luke Peterson, Robert Rolleri, Alice Gottlieb, Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Overview of 3 Randomized Controlled Trials , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Kristian Reich , April Armstrong , Yaowei Zhu, Megan Miller, Yin You, Yaung-Kaung Shen, Ya-Wen Yang, Peter Foley, Christopher Griffiths, Bruce Strober , Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Andrew Blauvelt, Lawrence Eichenfeld, Michael Kuligowski, May Venturanza, Kang Sun, Jonathan Silverberg, Long-term safety and disease control with ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Jonathan Silverberg, Thomas Bieber, Amy Paller, Lisa Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, Khaled Ezzedine, Peter Foley, Erin Johansson, Martin Dossenbach, Bülent Akmaz, Marta Casillas, Andrei Karlsson, Raj Chovatiya, Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: a Network Meta-Analysis , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 1 (2024): January 2024 Issue
Bruce Strober, Howard Sofen, Shinichi Imafuku, Carle Paul, Melinda Gooderham, Lynda Spelman, Seong Jun Seo, Thierry Passeron, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Matthias Augustin, Linda Stein Gold, Andrew Alexis, Diamant Thaçi, Andrew Blauvelt, Mark Lebwohl, Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue

<< < 1 2 3 4 5 6 7 8 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)